Results 261 to 270 of about 21,379,209 (297)

Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma

Current Cancer Drug Targets, 2022
Abstract:Mucin 1 (MUC 1) is a highly glycosylated tumor-associated antigen (TAA) overexpressed in hepatocellular carcinoma (HCC). This protein plays a critical role in various immune-mediated signaling pathways at its transcriptional and post-transcriptional levels, leading to immune evasion and metastasis in HCC.
Lekshmi R. Nath, Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, Reshma Ravindran Nair   +4 more
openaire   +2 more sources

Role of Mucin 1 and Glycodelin A in recurrent implantation failure

Fertility and Sterility, 2015
To evaluate and compare the levels of Mucin 1 (MUC-1) and Glycodelin A (GdA) in precisely timed endometrial biopsies and blood samples taken from women with recurrent implantation failure, and women with proven fertility, in a control group.Molecular studies in human blood and tissue.University hospital.Women with recurrent implantation failure and ...
Ercan Bastu, Mehmet F. Mutlu, Cenk Yasa, Ozlem Dural, Asli Nehir Aytan, Cem Celik, Faruk Buyru, John Yeh   +7 more
openaire   +2 more sources

Aptamer-Gated Ion Channel for Ultrasensitive Mucin 1 Detection

Analytical Chemistry, 2021
Detection of cancer markers is important for early diagnosis and timely treatment of cancer. In this study, we fabricated a tailorable gold nanofilm-anodized aluminum oxide (Au-AAO) ion channel through nanoparticle self-assembly and proposed a highly sensitive and selective Mucin 1 (MUC1) detection method.
Mengying Pan, Jiarong Cai, Si Li, Liguang Xu, Wei Ma, Chuanlai Xu, Hua Kuang   +6 more
openaire   +2 more sources

Update on Mucin-1 immunotherapy in cancer: a clinical perspective

Expert Opinion on Biological Therapy, 2015
Mucin 1 (MUC1) is particularly well suited as a cancer immunotherapy target due to the elevated protein expression and aberrant forms associated with malignancy. A variety of therapeutic strategies have been explored, including antibodies intended to induce cancer cell destruction, and vaccinations with peptides, tumor extracts, and gene expression ...
Gareth, Rivalland, Bruce, Loveland, Paul, Mitchell   +2 more
openaire   +2 more sources

Cancer specific Mucin‐1 glycoforms are expressed on multiple myeloma

British Journal of Haematology, 2006
SummaryPresent therapies cannot cure the large majority of patients with multiple myeloma (MM) and therefore new treatment strategies are imperative. This study analysed the different glycosylation profiles of Mucin‐1 (MUC1) on MM and acute myeloid leukaemia (AML) cells using a series of anti‐MUC1 antibodies.
Cloosen, S., Gratama, J., Leeuwen, E.B.M. van, Senden-Gijsbers, B.L.M.G., Oving, E.B.H., Mensdorff-Pouilly, S., Tarp, Mads Peter Agervig, Clausen, Ulla Marie Mandel, Clausen, H., Germeraad, W.T.V., Bos, G.M.J.   +10 more
openaire   +2 more sources

CTL in mice immunized with human mucin 1 are MHC-restricted

The Journal of Immunology, 1995
Abstract CTLs that recognize tumor Ags have been described in mice and humans, particularly for melanoma. These CTLs are CD8+, which is MHC-restricted. In contrast, in human carcinomas of the breast, pancreas, or ovary, and in multiple myeloma, CD8+ CTLs have been described that lyse targets expressing human MUC1 in a non-MHC ...
V, Apostolopoulos, B E, Loveland, G A, Pietersz, I F, McKenzie   +3 more
openaire   +2 more sources

Designer Tridentate Mucin 1 Aptamer for Targeted Drug Delivery

Journal of Pharmaceutical Sciences, 2012
A single-stranded DNA aptamer (APT) capable of targeting mucin 1 (MUC1) extracellular protein was modified to increase its drug delivery specificity toward MUC1 overexpressing cancer cell line, MCF7. The active targeting region of APT was truncated and variable repeats (one, two, or three) of this sequence were synthesized. An aptamer formed from three
Tan, L., Gee Neoh, K., Kang, E.-T., Choe, W.-S., Su, X.   +4 more
openaire   +2 more sources

Mucin-1-related T cell infiltration in colorectal carcinoma

Cancer Immunology, Immunotherapy, 1996
Mucins (MUC) are highly glycosylated molecules widely expressed on epithelia of different origins, including colonic mucosa. Altered glycosylation processes in tumour cells result in the exposure of normally cryptic peptide epitopes, which may then be recognized as tumour-specific antigens.
Mulder, W. M.C., Stukart, M. J., De Windt, E., Wagstaff, J., Scheper, R. J., Bloemena, E.   +5 more
openaire   +4 more sources

Synthesis and antibody recognition of mucin 1 (MUC1)-?-conotoxin chimera

Journal of Peptide Science, 2000
We synthesized and characterized new chimera peptides by inserting an epitope of the mucin 1 glycoprotein (MUC1) as a 'guest' sequence in the 'host' structure of alpha-conotoxin GI, a 13-residue peptide (ECCNPACGRHYSC) isolated from the venom of Conus geographus.
E, Drakopoulou, K, Uray, G, Mezö, M R, Price, C, Vita, F, Hudecz   +5 more
openaire   +2 more sources

Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection

Journal of Immunotherapy, 2001
The mucin MUC1 is greatly increased in breast cancer and is a potential target for immunotherapy. In mice, MUCI conjugated to oxidized mannan (MUC1-mannan fusion protein [M-FP]) targets the mannose receptor and induces a high frequency of cytotoxic T lymphocytes and anti-tumor responses.
Vaios, Karanikas, Grenville, Thynne, Paul, Mitchell, Chin-Swee, Ong, Dishan, Gunawardana, Robert, Blum, Julian, Pearson, Jodie, Lodding, Geoff, Pietersz, Russell, Broadbent, Brian, Tait, Ian F. C., McKenzie   +11 more
openaire   +3 more sources